Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND003 in Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT07275788Phase 1Recruiting
- Sponsor
- Regend Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing REGEND003 with Placebo (2 arms). Primary endpoint: Adverse Events associated with the Cell Therapy at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
REGEND003
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07275788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275788.